杭州泰格医药科技股份有限公司（股票代码：300347.SZ/3347.HK）是中国领先的综合生物制药研发服务供应商。自2004年成立以来，泰格医药已建立起完整的生物制药研发服务体系，拥有广泛、优质而紧密的客户及合作伙伴，并一直是中国临床合同研究组织全球化发展的先行者，全球影响力不断扩大。我们以服务创新、共筑健康为使命，致力于高效推进医药产品市场化进程，为全球患者和医生提供具有临床价值的创新疗法，造福人类健康。

HANGZHOU TIGERMED CONSULTING CO., LTD. (Stock Code: 300347.SZ/3347.HK) is a China-based

leading provider of comprehensive biopharmaceutical R&D services. Founded in 2004, Tigermed has established a comprehensive suite of biopharmaceutical R&D service offerings, high-quality relations with its customers, and a

broad network of partners. Moreover, the Company has been a pioneer in global expansion of China-based

clinical CROs, with a continuously expanding global presence. Tigermed’s mission is to improve  health  by 

accelerating  the  development  of  innovative  and effective  treatments  for  patients everywhere, and the Company is committed to promoting the efficient development of pharmaceutical products and providing innovative and

clinically valuable therapies to patients and physicians worldwide for the benefit of human health.

Headquartered in China, the Company has more than 60 subsidiaries and more than 100 offices, laboratories and R&D bases worldwide, including 17 overseas operation sites across 12 countries and regions in the Asia-Pacific

region, North America and Europe. Currently, Tigermed employs about 5000 professionals globally.

我们的使命 MISSION

服务创新，共筑健康

Serve healthcare partners through innovation, advance human health through excellence.

我们的愿景 VISION

成为最有影响力的CRO公司

To be recognized as the leading CRO

正直诚信、开放包容、专业创新、合作担当

Honest & Reliable、Open & Inclusive、Professional & Innovative、Collaborative & Accountable